Abstract:Samanta Catueno 1^ , Fadi G. Haddad 2^ , Branko Cuglievan 1^ 1 Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; 2 Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA ^ ORCID: Samanta Catueno, 0000-0002-0072-8603; Fadi G. Haddad, 0000-0002-9702-8485; Branko Cuglievan, 0000-0002-6917-2244. Comment on: Li J, Gao J, Liu A, et al . Homoharringtonine-Based Induction Regimen Improved the Remission Rate and Survival Rate in Chinese Childhood AML: A Report From the CCLG-AML 2015 Protocol Study. J Clin Oncol 2023;41:4881-92. Keywords: Homoharringtonine (HHT); leukemia; myeloid; maintenance Submitted Nov 01, 2023. Accepted for publication Jan 23, 2024. Published online Feb 23, 2024. doi: 10.21037/tp-23-536 Acute myeloid leukemia (AML) is a complex disease accounting for 15% to 20% of pediatric leukemia cases (1). Previous research has reported event-free survival (EFS) rates ranging from 53% to 63% and overall survival (OS) rates ranging from 63% to 74% in pediatric AML (2). Existing challenges in AML treatment encompass issues such as resistance to chemotherapy, therapy-related toxicity, the influence of infrequent molecular signatures and epigenetic mutations, challenges in recruiting patients for clinical trials, and delays in accessing treatment protocols designed for adults. Strategies to enhance this situation involve refining risk stratification through the use of more precise diagnostic tools like next-generation sequencing (NGS), creating targeted therapies to reduce the toxicity associated with conventional chemotherapy, and adjusting the age criteria for enrollment in adult trials (3-6). The Chinese Children's Leukemia Group-AML 2015 study, led by Jing Li, evaluated the effectiveness and safety of different treatment protocols for pediatric AML (7). Notably, this comprehensive, multicenter, open-label study spanning 35 centers across China explored the use of two specific treatments: homoharringtonine (HHT also known as omacetaxine), commonly used in adult AML in China; and all-trans retinoic acid (ATRA), known for its efficacy in treating acute promyelocytic leukemia. This study sought to clarify whether HHT-based induction therapy is safe and effective in pediatric AML and whether ATRA-based maintenance therapy is effective in patients with non-acute promyelocytic leukemia AML. This study is intriguing because it proposes alternative therapeutic approaches, such as the use of HHT, the use of etoposide in induction and the use of maintenance, that deviate from the established standard of care within the Children's Oncology Group protocols (AAML1831). In this study, children with newly diagnosed AML were randomly assigned to either an HHT-based (H-arm) or an etoposide-based (E-arm) induction regimen. The first phase (Induction I) involved the administration of VP-16 (etoposide, 100 mg/m 2 daily) or HHT (3 mg/m 2 daily) on days 1 to 5. Additionally, daunorubicin was given at a dose of 40 mg/m 2 daily on days 1, 3, and 5, and cytarabine was administered at a dosage of 100 mg/m 2 every 12 hours on days 1 to 7. For the induction II phase (E arm, idarubicin plus cytarabine plus etoposide; H arm, idarubicin plus cytarabine plus HHT), idarubicin was administered once daily at a dose of 10 mg/m 2 on days 1, 3, and 5, substituting daunorubicin. Following induction therapy, all patients received 3 courses of consolidation therapy, which included various regimens: mitoxantrone plus cytarabine, HHT plus cytarabine, and cytarabine plus L-asparaginase. High-risk patients ineligible for hematopoietic stem cell transplantation received an additional course of HHT plus cytarabine (7). For maintenance therapy, patients who did not undergo hematopoietic stem cell transplantation were randomly assigned to ATRA-based (AT-arm) or cytarabine-based (AC-arm) therapy for approximately 1 year. In the AT arm, therapy consisted of daily oral doses of ATRA (20–30 mg/m 2 ) for the first 2 weeks and daily oral 6-mercaptopurine (50 mg/m 2 ) for the following 10 weeks. In the AC arm, therapy consisted of intravenous cytarabine (40 mg/m 2 ) administered daily on days 1 to 4 every 4 weeks and oral 6-mercaptopurine (50 mg/m 2 ) given once daily throughout the entire maintenance period. Each cycle lasted 12 weeks, and patients completed four cycles. The primary endpoint of the study was the complete remission rate following induction therapy, and the secondary endpoints were the OS and EFS rates. Importantly, the study was initially designed as a multicenter, randomized, controlled trial, but it was changed to a multicenter, prospective, observational clinical trial due to an unexpected, 6-month HHT shortage. Consequ -Abstract Truncated-

A homoharringtonine-based regimen for childhood acute myelogenous leukemia.

Homoharringtonine-based induction regimens for patients with de-novo acute myeloid leukaemia: a multicentre, open-label, randomised, controlled phase 3 trial

Homoharringtonine in Combination with Cytarabine and Aclarubicin in the Treatment of Refractory/Relapsed Acute Myeloid Leukemia: a Single-Center Experience

Trisomy 21 in Patients with Acute Leukemia

Homoharringtonine Based Induction Regimens for Patients with De Novo Acute Myeloid Leukemia: A Multicenter Randomized Controlled Phase 3 Trial

The Efficacy and Safety of a Homoharringtonine-Based Protocol for Children with Acute Myeloid Leukemia: A Retrospective Study in China

Homoharringtonine Based Triple-Drug Regimen As Induction Chemotherapy for De Novo Acute Myelogenous Leukemia.

Treatment of Childhood Leukemia with Unrelated Donor Allogeneic Bone Marrow Transplantation

Homoharringtonine is a Safe and Effective Substitute for Anthracyclines in Children Younger Than 2 Years Old with Acute Myeloid Leukemia

Long-Term Follow-Up of Treatment Outcome and Prognosis in 96 Chinese Children with Acute Myeloid Leukemia: A Single Center Experience.

Retrospective Study on 46 Chinese Children with Acute Promyelocytic Leukemia: A Single Center Experience in China.

Homoharringtonine-Based Induction Regimen Improved the Remission Rate and Survival Rate in Chinese Childhood AML: A Report From the CCLG-AML 2015 Protocol Study

Outcome Of B-Cell Non-Hodgkin Lymphoma Protocol Cccg-B Nhl97: A Report From Chinese Multi-Center Cooperative Group

The efficacy of homoharringtonine in pediatric acute myeloid leukemia: findings from the Chinese Children's Leukemia Group-AML 2015 Study

Long-Term Outcome of Childhood Acute Myeloid Leukemia Treated in China

Homoharringtonine-Based Induction Regimens Combined with ATRA-Based Maintenance in Chinese Pediatric AML: A Report from the Cclg-AML 2015 Protocol Study

Homoharringtonine as a backbone drug for the treatment of newly diagnosed pediatric acute myeloid leukemia: a report from a single institution in China

Long-term Outcome of Childhood Acute Myeloid Leukemia in a Developing Country: Experience from a Children's Hospital in China

A Multicenter Randomized Non-Inferiority Study of Homoharringtonine Versus Etoposide in Induction Phase for Chinese Childhood Acute Myeloid Leukemia - a Report from China Children's Leukemia Group (CCLG)

[Long-Term Follow-Up of Treatment Outcome and Prognosis on 46 Children with Acute Promyelocytic Leukemia].

Could Anthracycline Be Replaced in Chemotherapy for Acute Myeloid Leukemia? Randomized Clinical Trial of Homoharringtonine As Frontline Agent to Treat Pediatric Aml